Videos

Linda Vahdat, MD, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB.

Katherine Van Loon, MD, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.

Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.

Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.

Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.

Joanne Blum, MD, PhD, discusses the function of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer.

Sabine Siesling discusses breast conserving surgery versus mastectomy. Siesling says her and her team found that internationally, the survival rate of breast cancer patients is lower when a mastectomy is performed, as compared to breast conserving surgery.

​Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways.

Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin.

Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.

​Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.

Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.

Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

William Sikov, MD, associate director of Clinical Research, Program in Women